Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
🌎 Global
Global
United States
Australia
United Kingdom
Canada
India
China
Argentina
Austria
Bahrain
Bangladesh
Belgium
Bermuda
Botswana
Brazil
Bulgaria
Chile
Colombia
Croatia
Cyprus
Czech Republic
Denmark
Egypt
Estonia
Finland
France
Germany
Ghana
Greece
Hong Kong
Hungary
Iceland
Indonesia
Ireland
Israel
Italy
Ivory Coast
Jamaica
Japan
Jordan
Kenya
Kuwait
Latvia
Lithuania
Luxembourg
Malawi
Malaysia
Malta
Mauritius
Mexico
Morocco
Namibia
Netherlands
New Zealand
Nigeria
Norway
Oman
Pakistan
Palestinian Authority
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russia
Saudi Arabia
Serbia
Singapore
Slovakia
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Taiwan
Tanzania
Thailand
Trinidad & Tobago
Tunisia
Turkey
Uganda
Ukraine
United Arab Emirates
Venezuela
Vietnam
Zambia
Zimbabwe
Create a narrative
Global Community
Our community narratives are driven by numbers and valuation.
Create a narrative
Community Investing Ideas
Global Weekly Picks
Airbnb
TI
TickerTickle
Community Contributor
Airbnb (ABNB): Still one of the most interesting bets in travel
Key insights Airbnb is changing from a travel-only app to a full lifestyle platform (stays, rentals, experiences) International markets are growing faster than the US, which is slowing down Product experience is improving a lot, with AI making search and booking easier Regulations are becoming a big risk, especially in Europe where listings are getting removed The way people move around the world has changed. It’s not only about holidays anymore.
View narrative
US$163.75
FV
23.6% undervalued
intrinsic discount
12.00%
Revenue growth p.a.
Set Fair Value
13
users have liked this narrative
8
users have commented on this narrative
49
users have followed this narrative
New
narrative
ING Groep
PI
PittTheYounger
Community Contributor
ING leads the pack when it comes to pivoting towards non-lending income
ING, of course, is a bank; and banks don't like falling interest rates, right? For the dominant stream of income is their core business model, i.e. borrowing short-term and lending long-term, reaping the difference in interest rates in the process.
View narrative
€27.92
FV
24.2% undervalued
intrinsic discount
9.00%
Revenue growth p.a.
Set Fair Value
7
users have liked this narrative
0
users have commented on this narrative
18
users have followed this narrative
New
narrative
Coles Group
RO
Robbo
Community Contributor
Coles (ASX: COL): Safe, Steady, and Surprisingly Cheap
The supermarket chain Coles is the kind of “boring” business that may have been overlooked as an investment opportunity. Although it was divested from Wesfarmers in 2018, Coles’ heritage traces back to 1914 — giving it over 110 years of history.
View narrative
AU$22.00
FV
4.4% undervalued
intrinsic discount
8.72%
Revenue growth p.a.
Set Fair Value
6
users have liked this narrative
2
users have commented on this narrative
17
users have followed this narrative
New
narrative
All companies
Popular
Undervalued
Overvalued
Load previous narratives
Planet Labs PBC
AN
AnalystLowTarget
Consensus Narrative from 10 Analysts
Rising Regulations And Cost Pressures Will Constrain Geospatial Markets
Key Takeaways Regulatory and data sovereignty challenges threaten recurring revenue growth and global market share, especially as clients grow wary of data privacy and compliance issues. Profitability struggles persist due to high operating costs and reliance on a few government contracts, increasing vulnerability to budget shifts and new market entrants.
View narrative
US$4.50
FV
50.7% overvalued
intrinsic discount
16.66%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
2 days ago
author updated this narrative
Curaleaf Holdings
AN
AnalystLowTarget
Consensus Narrative from 6 Analysts
Intensified Global Regulation Will Squeeze Cannabis Margins Despite European Hopes
Key Takeaways Intensifying regulatory scrutiny, price compression, and new competitors threaten margins, market share, and long-term profitability. Heavy investment and macroeconomic headwinds risk ongoing negative cash flow and shrinking shareholder value.
View narrative
CA$2.65
FV
38.6% overvalued
intrinsic discount
4.14%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
2 days ago
author updated this narrative
Viasat
AN
AnalystLowTarget
Consensus Narrative from 7 Analysts
GEO Broadband Will Suffer Amid LEO And 5G Challenges
Key Takeaways Mounting competition from LEO satellites and terrestrial networks is eroding Viasat's market share, pressuring subscriber growth and revenue sustainability. Heavy investment demands, operational risks, and regulatory challenges threaten cash flow, margins, and future capacity expansion.
View narrative
US$10.00
FV
171.0% overvalued
intrinsic discount
2.73%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
2 days ago
author updated this narrative
Weave Communications
AN
AnalystLowTarget
Consensus Narrative from 7 Analysts
Healthcare Headwinds Will Limit Margins While Automation Will Yield Relief
Key Takeaways Heavy reliance on healthcare verticals and rising competition expose Weave to revenue instability, margin pressure, and challenges in sustaining long-term growth. Acquisition integration risks, customer churn, and evolving compliance demands may delay profitability improvements and threaten efficient operating leverage.
View narrative
US$9.00
FV
13.4% undervalued
intrinsic discount
15.32%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
2 days ago
author updated this narrative
CareDx
AN
AnalystLowTarget
Consensus Narrative from 5 Analysts
New Medicare Policies Will Erode Margins Despite Digital Gains
Key Takeaways Imminent shifts in reimbursement policies and industry consolidation threaten CareDx's pricing power, gross margins, and future revenue scalability. Growing regulatory scrutiny and increased competition in transplant diagnostics may slow market share gains and place long-term pressure on earnings momentum.
View narrative
US$14.00
FV
15.4% undervalued
intrinsic discount
12.35%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
2 days ago
author updated this narrative
Maravai LifeSciences Holdings
AN
AnalystLowTarget
Consensus Narrative from 8 Analysts
Rising Regulatory Burdens Will Weaken mRNA Base Despite BST Gains
Key Takeaways Heavy reliance on core technologies and clients leaves Maravai vulnerable to market shifts, technological disruption, and increasing vertical integration among major biopharma partners. Rising competition, regulatory costs, and market commoditization threaten profitability and long-term growth, especially as research funding migrates to regions with weaker Maravai presence.
View narrative
US$2.00
FV
30.5% overvalued
intrinsic discount
-0.15%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
2 days ago
author updated this narrative
TechTarget
AN
AnalystLowTarget
Consensus Narrative from 3 Analysts
Client Concentration Will Constrain Margins Yet Yield Cautious Recovery
Key Takeaways Reliance on key clients and growing industry competition threaten revenue stability, while technological advances may erode pricing power and market differentiation. Data privacy regulations and content proliferation risk undermining data collection, lead generation, and long-term earnings potential despite digital transformation tailwinds.
View narrative
US$10.00
FV
39.0% undervalued
intrinsic discount
17.04%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
2 days ago
author updated this narrative
Delek US Holdings
AN
AnalystLowTarget
Consensus Narrative from 12 Analysts
Shifting EV Demand And Cost Hikes Will Weaken Refining Operations
Key Takeaways Shifting regulations, fuel demand decline, and aging assets put Delek at a structural disadvantage versus diversified competitors, risking persistent earnings challenges and market share erosion. Increased costs from emissions controls, investor divestment, and capital constraints threaten long-term shareholder value and Delek's ability to effectively finance growth.
View narrative
US$14.00
FV
55.4% overvalued
intrinsic discount
-3.66%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
2 days ago
author updated this narrative
Ocular Therapeutix
AN
AnalystLowTarget
Consensus Narrative from 11 Analysts
Regulatory Risks Will Hinder Ophthalmology Trials Yet Future Upside Emerges
Key Takeaways Heavy reliance on a single lead therapy exposes the company to regulatory and clinical risks that could threaten future revenue and earnings stability. Competitive pressures, payer cost controls, and potential generic entrants could limit pricing power, slow market expansion, and impact long-term margin growth.
View narrative
US$14.00
FV
9.9% undervalued
intrinsic discount
12.42%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
2 days ago
author updated this narrative
Value any company in seconds
Popular companies